COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $10,795 | $8,868 | $7,930 | $11,649 |
| - Cash | $9,333 | $13,759 | $16,393 | $19,998 |
| + Debt | $2,258 | $2,226 | $2,310 | $1,616 |
| Enterprise Value | $3,720 | -$2,665 | -$6,153 | -$6,733 |
| Revenue | $2,749 | $1,495 | $3,322 | $1,871 |
| % Growth | 83.8% | -55% | 77.6% | – |
| Gross Profit | $974 | $442 | $2,049 | $837 |
| % Margin | 35.4% | 29.5% | 61.7% | 44.7% |
| EBITDA | -$2,390 | -$3,250 | -$5,234 | -$5,366 |
| % Margin | -86.9% | -217.3% | -157.6% | -286.8% |
| Net Income | -$2,701 | -$3,644 | -$6,731 | -$5,755 |
| % Margin | -98.3% | -243.7% | -202.6% | -307.6% |
| EPS Diluted | -0.85 | -1.16 | -2.35 | -1.85 |
| % Growth | 26.7% | 50.6% | -27% | – |
| Operating Cash Flow | -$4,447 | -$1,874 | -$2,999 | -$7,779 |
| Capital Expenditures | -$49 | -$613 | -$309 | -$131 |
| Free Cash Flow | -$4,496 | -$2,487 | -$3,308 | -$7,910 |